25 Nov 2024
Impact of late-breaking clinical evidence on your daily mitral TEER practice
Supported by Edwards Lifesciences
Summary
In this roundtable discussion, Tobias Geisler, Maurizio Taramasso, and Robert Smith delve into the late-breaking trials presented at PCR London Valves 2024. They examine the CLASP IID study, which compares TEER devices for severe mitral regurgitation, and the MiCLASP study, evaluating edge-to-edge therapy approaches. Together, they explore the impact of these findings on clinical practice and patient care.
This interview was filmed at PCR London Valves 2024: see more videos here.